USA flag logo/image

An Official Website of the United States Government

SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
N43CA130037
Solicitation Year:
2013
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
ADAPTIVE TCR CORPORATION
1551 Eastlake Avenue East Suite 200 SEATTLE, WA 98102-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE
Agency: HHS
Contract: N43CA130037
Award Amount: $266,199.00
 

Abstract:

Immunotherapy has emerged as a promising method to treat several cancers. In 2012 the FDA approved a new immunotherapy agent, ipilimumab, for metastatic melanoma. Ipilimumab activates T-cells and globally increases the adaptive immune response and resultsin an enhanced response to the cancer. In a subset of patients, this leads to longer Progression Free Survival (PFS), and in some cases remission. However, there is no companion diagnostic available to predict responders. The goal of this project is to develop a deep sequencing assay to measure the immune repertoire and a corresponding diagnostic protocol that differentiates ipilimumab responders from non-responders. Currently, while many of patients experience immune mediated side effects related to ipilimumab, less than 10% of patients cancer responds to therapy. Developing a companion diagnostic that differentiates responders from non-responders would protect non-responders from unnecessary side-effects. PUBLIC HEALTH RELEVANCE

Principal Investigator:

Mark Rieder
206-659-0067
MRIEDER@ADAPTIVEBIOTECH.COM

Business Contact:

Mark Rieder
206-659-0067
MRIEDER@ADAPTIVEBIOTECH.COM
Small Business Information at Submission:

ADAPTIVE TCR CORPORATION
1551 Eastlake Avenue East Suite 200 SEATTLE, WA 98102-

EIN/Tax ID: 127090702
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No